Sialic acid <i>cis</i> -ligand dynamics modulate Siglec-7 and -9 function and affect Siglec-7/9 co-blockade to potentiate natural killer cell anti-tumor activity
-interactions and emphasize the potential of simultaneously blocking Siglec-7 and -9 for clinical applications. These insights may guide the design of next-generation Siglec-targeted immunotherapies.
Authors
- Anna E. Marneth (ORCID: https://orcid.org/0000-0001-9065-0581)
- Christian Büll (ORCID: https://orcid.org/0000-0001-7785-2920)
- Gosse J. Adema (ORCID: https://orcid.org/0000-0002-6750-1665)
- Lenneke A. M. Cornelissen (ORCID: https://orcid.org/0000-0003-2210-1606)
- Harry Dolstra (ORCID: https://orcid.org/0000-0002-3998-687X)
- Eline J.H. van Houtum (ORCID: https://orcid.org/0000-0001-9037-4388)
- Jesper van Eck van der Sluijs (ORCID: https://orcid.org/0000-0003-3136-7799)
- W Hobo
- Anne H. C. Valk
- Lune van den Boogaard
- Maaike Looman
- Esther D. Kers-Rebel
Institutions
- Radboud University Nijmegen (NL)
- Radboud University Medical Center (NL)
- Radboud Institute for Molecular Life Sciences (NL)
Publication Details
- Journal
- OncoImmunology
- Published
- 2026-04-02
- DOI
- https://doi.org/10.1080/2162402x.2026.2649988
- Primary Topic
- Glycosylation and Glycoproteins Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- KWF Kankerbestrijding
- Radboud Universitair Medisch Centrum